AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34617505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral and well-being therapy (CBT/WBT)
Number of subjects: 288
Study 34617505 — intervention group
Group type: COMPARATOR
Intervention: Clinical management (CM)
Number of subjects: 288
Study 34380811 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized obturator
Number of subjects: 48
Study 34380811 — intervention group
Group type: COMPARATOR
Intervention: Conventional obturator
Number of subjects: 48
Study 34380811 — intervention group
Group type: COMPARATOR
Intervention: Without obturator
Number of subjects: 48
Study 32176397 — intervention group
Group type: EXPERIMENTAL
Intervention: Years of education (measured by additional year of education)
Number of subjects: 1651
Study 34973240 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group (tamsulosin (0.2 mg/day) plus mirabegron (50 mg/day))
Number of subjects: 218
Study 34973240 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin‐alone group
Number of subjects: 218
Study 34973240 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention rates
Number of subjects: 218
Study 34085479 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-tissue thread embedding therapy
Number of subjects: 70
Study 34085479 — intervention group
Group type: COMPARATOR
Intervention: Shallow-tissue thread embedding therapy
Number of subjects: 70
Study 35109898 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet noninvasive ventilation with usual care
Number of subjects: 320
Study 35109898 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (which may include mask noninvasive ventilation, high-flow nasal oxygen, or standard oxygen therapy)
Number of subjects: 320
Study 34774052 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuma longa extract (CLE)
Number of subjects: 90
Study 34774052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 32585907 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated Sprint Training (RST)
Number of subjects: 36
Study 32585907 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated High-Intensity Technique Training (RTT)
Number of subjects: 36
Study 32585907 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 36
Study 36449671 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser‐assisted cataract surgery (FLACS)
Number of subjects: 86
Study 36449671 — intervention group
Group type: COMPARATOR
Intervention: Conventional phacoemulsification (CPS)
Number of subjects: 86
Study 32143216 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigational template
Number of subjects: 120
Study 32143216 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 120
Study 33302654 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet plus graded diagnosis and treatment strategy
Number of subjects: 300
Study 33302654 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study 36116480 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg linzagolix per day alone
Number of subjects: 1042
Study 36116480 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg linzagolix per day with hormonal add-back therapy (1 mg oestradiol and 0.5 mg norethisterone acetate)
Number of subjects: 1042
Study 36116480 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg linzagolix per day alone
Number of subjects: 1042
Study 36116480 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg linzagolix per day with hormonal add-back therapy (1 mg oestradiol and 0.5 mg norethisterone acetate)
Number of subjects: 1042
Study 36116480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1042
Study 34032151 — intervention group
Group type: EXPERIMENTAL
Intervention: Yukgunja-Tang (YGJT) administered at 3.0 g twice a day for 4 weeks (total of 56 times)
Number of subjects: 40
Study 34032151 — intervention group
Group type: EXPERIMENTAL
Intervention: Yukgunja-Tang (YGJT)
Number of subjects: 40
Study 34032151 — intervention group
Group type: COMPARATOR
Intervention: Nutrition counseling
Number of subjects: 40
Study 35379300 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 543
Study 35379300 — intervention group
Group type: COMPARATOR
Intervention: Intermittent hemodialysis (IHD)
Number of subjects: 543
Study 34069981 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 g·d−1 β-alanine (BA) for four weeks
Number of subjects: 15
Study 34069981 — intervention group
Group type: COMPARATOR
Intervention: Placebo for four weeks
Number of subjects: 15
Study 35342997 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg once daily (QD) for 6 weeks
Number of subjects: 531
Study 35342997 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg once daily (QD) for 6 weeks
Number of subjects: 531
Study 35342997 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg twice daily (BID) for 2 weeks followed by QD for 4 weeks
Number of subjects: 531
Study 35342997 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg BID for 2 weeks followed by QD for 4 weeks
Number of subjects: 531
Study 32970265 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35186107 — intervention group
Group type: EXPERIMENTAL
Intervention: Lianhua Qingke (LH) tablets (4 tablets, three times a day for 14 days)
Number of subjects: 144
Study 35186107 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine treatment without LH tablets)
Number of subjects: 144
Study 35737911 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance after autologous transplantation (ASCT)
Number of subjects: 300
Study 35737911 — intervention group
Group type: COMPARATOR
Intervention: Observation after autologous transplantation (ASCT)
Number of subjects: 300
Study 35737911 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD analysis using BM
Number of subjects: 300
Study 35737911 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD analysis using PB
Number of subjects: 300
Study 35737911 — intervention group
Group type: EXPERIMENTAL
Intervention: Time‐varying kinetic model based on MRD results and Mantle Cell Lymphoma International Prognostic Index
Number of subjects: 300
Study 35737911 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD as a predictor
Number of subjects: 300
Study 33556032 — intervention group
Group type: EXPERIMENTAL
Intervention: MeCOVID (melatonin)
Number of subjects: 206
Study 33556032 — intervention group
Group type: EXPERIMENTAL
Intervention: EPICOS (tenofovir disoproxil/emtricitabine vs hydroxychloroquine vs combination therapy vs placebo)
Number of subjects: 206
Study 33556032 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 206
Study 32503727 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson (A2AR agonist), continuous infusion starting at the time of skin incision, maximum dose of 1.44 µg/kg/min for 12 hours
Number of subjects: 14
Study 35648046 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-Integrated Mindfulness-Based Relapse Prevention (TI-MBRP)
Number of subjects: 83
Study 35648046 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness-Based Relapse Prevention (MBRP)
Number of subjects: 83
Study 35648046 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TI-MBRP and MBRP
Number of subjects: 83
Study 34256698 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized interventions delivered by the iCARE system (using comics, videos, pictures, text) in addition to standard care
Number of subjects: 2820
Study 34256698 — intervention group
Group type: COMPARATOR
Intervention: Modified iCARE (only text) in addition to routine care
Number of subjects: 2820
Study 34256698 — intervention group
Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 2820
Study 33837574 — intervention group
Group type: EXPERIMENTAL
Intervention: Soticlestat oral solution, single ascending doses up to 1350 mg
Number of subjects: 48
Study 33837574 — intervention group
Group type: EXPERIMENTAL
Intervention: Soticlestat tablets under fed conditions
Number of subjects: 48
Study 33837574 — intervention group
Group type: EXPERIMENTAL
Intervention: Soticlestat tablets under fasting conditions
Number of subjects: 48
Study 33837574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 36060668 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS combined with CACT
Number of subjects: 86
Study 36060668 — intervention group
Group type: COMPARATOR
Intervention: TMS
Number of subjects: 86
Study 35126747 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with lavender essential oil
Number of subjects: 60
Study 35126747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 35126747 — intervention group
Group type: COMPARATOR
Intervention: Comparison between intervention and placebo groups
Number of subjects: 60
Study 34655698 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 207946
Study 34655698 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 207946
Study 34655698 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 207946
Study 34655698 — intervention group
Group type: COMPARATOR
Intervention: Other antidepressants (fluoxetine, paroxetine, escitalopram, citalopram, duloxetine, moclobemide, mirtazapine, bupropion)
Number of subjects: 207946
Study 35617246 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural risk factors of suicide at Time 1
Number of subjects: 449
Study 35617246 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural stressors of suicide and depression
Number of subjects: 449
Study 33231771 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized post-coercion review session
Number of subjects: 82
Study 33231771 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 82
Study 35800224 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia (group III)
Number of subjects: 40
Study 35800224 — intervention group
Group type: COMPARATOR
Intervention: Propofol anesthesia with sinus rhythm (group I)
Number of subjects: 40
Study 35800224 — intervention group
Group type: COMPARATOR
Intervention: Propofol anesthesia with atrial fibrillation rhythm (group II)
Number of subjects: 40
Study 35800224 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia with atrial fibrillation rhythm (group IV)
Number of subjects: 40
Study 32045010 — intervention group
Group type: EXPERIMENTAL
Intervention: OSA patients without treatment
Number of subjects: 3978
Study 32045010 — intervention group
Group type: EXPERIMENTAL
Intervention: OSA patients with treatment (continuous positive airway pressure or surgery)
Number of subjects: 3978
Study 32045010 — intervention group
Group type: COMPARATOR
Intervention: Non-OSA patients
Number of subjects: 3978
Study 33051276 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency treatment with Levetiracetam or Phenytoin
Number of subjects: 143
Study 33051276 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent and practitioner support for EcLiPSE recruitment
Number of subjects: 143
Study 33051276 — intervention group
Group type: EXPERIMENTAL
Intervention: Research without prior consent processes
Number of subjects: 143
Study 33051276 — intervention group
Group type: EXPERIMENTAL
Intervention: Practitioner motivation and strong leadership
Number of subjects: 143
Study 33051276 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of leadership
Number of subjects: 143
Study 33051276 — intervention group
Group type: EXPERIMENTAL
Intervention: EcLiPSE trial completion
Number of subjects: 143
Study 32640554 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Nature (VN) group
Number of subjects: 77
Study 32640554 — intervention group
Group type: COMPARATOR
Intervention: Virtual Abstract Painting (VAP) group
Number of subjects: 77
Study 35487792 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D Supplementation (4,000 IU daily for 30 days)
Number of subjects: 321
Study 35487792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study 35487792 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D Supplementation
Number of subjects: 321
Study 34098739 — intervention group
Group type: EXPERIMENTAL
Intervention: Twirla (2.3 mg ethinyl estradiol and 2.6 mg levonorgestrel)
Number of subjects: 0
Study 34098739 — intervention group
Group type: EXPERIMENTAL
Intervention: Twirla
Number of subjects: 0
Study 35454330 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer group (PG)
Number of subjects: 26
Study 35454330 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 26
Study 34465469 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS 50 (light anaesthesia)
Number of subjects: 655
Study 34465469 — intervention group
Group type: COMPARATOR
Intervention: BIS 35 (deep anaesthesia)
Number of subjects: 655
Study 36352762 — intervention group
Group type: EXPERIMENTAL
Intervention: Tregopil 30 mg
Number of subjects: 91
Study 36352762 — intervention group
Group type: EXPERIMENTAL
Intervention: Tregopil 45 mg
Number of subjects: 91
Study 36352762 — intervention group
Group type: COMPARATOR
Intervention: Insulin Aspart (IAsp)
Number of subjects: 91
Study 36352762 — intervention group
Group type: EXPERIMENTAL
Intervention: Tregopil (combined group)
Number of subjects: 91
Study 36352762 — intervention group
Group type: EXPERIMENTAL
Intervention: Tregopil
Number of subjects: 91
Study 34134835 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure
Number of subjects: 200
Study 34134835 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 200
Study 34134835 — intervention group
Group type: COMPARATOR
Intervention: Avoidant class
Number of subjects: 200
Study 32384397 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe COVID-19 pneumonia
Number of subjects: 260
Study 35028513 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU/day vitamin D supplementation (group A, n=120)
Number of subjects: 350
Study 35028513 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU/day vitamin D supplementation (group B, n=115)
Number of subjects: 350
Study 35028513 — intervention group
Group type: COMPARATOR
Intervention: 400 IU/day vitamin D supplementation (group C, n=115)
Number of subjects: 350
Study 35028513 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of serum 25(OH)D levels
Number of subjects: 350
Study 33158423 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral neuromuscular training with an oral device (Muppy®) for 5 weeks
Number of subjects: 40
Study 33158423 — intervention group
Group type: COMPARATOR
Intervention: Control group with continued orofacial sensory-vibration stimulation with an electric toothbrush for 5 weeks
Number of subjects: 40
Study 35150773 — intervention group
Group type: EXPERIMENTAL
Intervention: SCARF intervention (multidisciplinary residential rehabilitation)
Number of subjects: 0
Study 33579525 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin stimulation in cultures of normal human granulosa cells in vitro
Number of subjects: 40
Study 33579525 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin concentration of 100 nmol/L for 12 hours
Number of subjects: 40
Study 35729713 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozoralizumab 30 mg
Number of subjects: 381
Study 35729713 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozoralizumab 80 mg
Number of subjects: 381
Study 35729713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study 32179153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM) 0.2 mg
Number of subjects: 92
Study 32179153 — intervention group
Group type: COMPARATOR
Intervention: Control (2 ml of 0.9% saline)
Number of subjects: 92
Study 35370933 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nursing and health education (INHE)
Number of subjects: 68
Study 33241482 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT)
Number of subjects: 0
Study 33241482 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 0
Study 34585222 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-domain intervention program including management of vascular risk factors, group-based physical exercise, nutritional counseling, and cognitive training
Number of subjects: 500
Study 34585222 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-domain intervention program
Number of subjects: 500
Study 34585222 — intervention group
Group type: COMPARATOR
Intervention: Health-related information provided every two months
Number of subjects: 500
Study 32507029 — intervention group
Group type: EXPERIMENTAL
Intervention: Pineapple juice
Number of subjects: 0
Study 32507029 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study 34520637 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT)
Number of subjects: 39
Study 34520637 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 39
Study 32759439 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectoral nerve block with ropivacaine 0.375% 30 ml
Number of subjects: 60
Study 32759439 — intervention group
Group type: COMPARATOR
Intervention: Thoracic paravertebral block with ropivacaine 0.5% 20 ml
Number of subjects: 60
Study 33092947 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lidocaine spray
Number of subjects: 376
Study 33092947 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel
Number of subjects: 376
Study 33092947 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lidocaine with xylometazoline (1:1) soaked pledgets
Number of subjects: 376
Study 33092947 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous gel
Number of subjects: 376
Study 33092947 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 376
Study 32658083 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on identified risk factors (male sex, smoking history, history of severe acute pancreatitis, chronic pain at/before diagnosis of ICP, complex pathologic changes in main pancreatic duct)
Number of subjects: 1633
Study 35164853 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Bushen Yiqi formula (MBYF) as an add-on to budesonide/formoterol
Number of subjects: 0
Study 35164853 — intervention group
Group type: COMPARATOR
Intervention: Placebo as an add-on to budesonide/formoterol
Number of subjects: 0
Study 33111980 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone-autohemotherapy
Number of subjects: 28
Study 33111980 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study 33558090 — intervention group
Group type: EXPERIMENTAL
Intervention: MiS coupled with VPA for predicting hot carcase P8 fat depth
Number of subjects: 1274
Study 33558090 — intervention group
Group type: EXPERIMENTAL
Intervention: MiS coupled with VPA for predicting cold carcase rib fat
Number of subjects: 1274
Study 33558090 — intervention group
Group type: EXPERIMENTAL
Intervention: MiS coupled with OCP for predicting hot carcase P8 fat depth
Number of subjects: 1274
Study 33308429 — intervention group
Group type: COMPARATOR
Intervention: Monovalent OPV2 (1 or 2 doses)
Number of subjects: 300
Study 33308429 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel OPV2‐c1 (1 or 2 doses)
Number of subjects: 300
Study 33308429 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel OPV2‐c2 (1 or 2 doses)
Number of subjects: 300
Study 33308429 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel OPV2‐c1 (2 doses) in IPV-vaccinated participants
Number of subjects: 300
Study 33308429 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel OPV2‐c2 (2 doses) in IPV-vaccinated participants
Number of subjects: 300
Study 33308429 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 doses) in IPV-vaccinated participants
Number of subjects: 300
Study 33308429 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel OPV2 candidates (1 dose)
Number of subjects: 300
Study 33308429 — intervention group
Group type: COMPARATOR
Intervention: Monovalent OPV2 (1 dose)
Number of subjects: 300
Study 33185706 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated deep learning and level set method for pulp chamber segmentation
Number of subjects: 180
Study 33185706 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated deep learning and level set method for age estimation
Number of subjects: 180
Study 32472255 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + GPS
Number of subjects: 72
Study 32472255 — intervention group
Group type: EXPERIMENTAL
Intervention: GPS + RT
Number of subjects: 72
Study 32472255 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + Biodentine
Number of subjects: 72
Study 32472255 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine + RT
Number of subjects: 72
Study 32472255 — intervention group
Group type: COMPARATOR
Intervention: Intact/non-irradiated teeth
Number of subjects: 72
Study 32857113 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implant
Number of subjects: 100
Study 35441926 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group with support tool app for medication intake reminders and motivational messages
Number of subjects: 676
Study 35441926 — intervention group
Group type: COMPARATOR
Intervention: Control group without support tool app
Number of subjects: 676
Study 35441926 — intervention group
Group type: COMPARATOR
Intervention: Both groups (active and control)
Number of subjects: 676
Study 35441926 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group
Number of subjects: 676
Study 35441926 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 676
Study 34903034 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3005
Study 34903034 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 3005
Study 34658033 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation ON (n=8)
Number of subjects: 18
Study 34658033 — intervention group
Group type: COMPARATOR
Intervention: Stimulation OFF (n=10)
Number of subjects: 18
Study 32831984 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intravenous infusion of 5 mg zoledronic acid (ZOL)
Number of subjects: 242
Study 32831984 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ZOL)
Number of subjects: 242
Study 36152527 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling (DN)
Number of subjects: 38